Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders

Thrombopoietin (TPO), a potent stimulator of megakaryocyte and platelet production, has been used in clinical trials to reduce thrombocytopenia after chemotherapy in patients with acute myeloid leukemia (AML). We report that TPO therapy is associated with peripheral blood and bone marrow findings th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of clinical pathology 2002-06, Vol.117 (6), p.844-850
Hauptverfasser:	DOUGLAS, Vonda K, TALLMAN, Martin S, CRIPE, Larry D, PETERSON, LoAnn C
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Aged Aged, 80 and over Biological and medical sciences Bone Marrow - drug effects Bone Marrow - pathology Drug Therapy, Combination Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Hematologic and hematopoietic diseases Humans Leukemia, Myeloid - complications Leukemia, Myeloid - drug therapy Leukemia, Myeloid - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Megakaryocytes - drug effects Megakaryocytes - pathology Middle Aged Myeloproliferative Disorders - chemically induced Myeloproliferative Disorders - pathology Neoadjuvant Therapy - adverse effects Retrospective Studies Thrombopoietin - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!